UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

OMB APPROVAL		
OMB Number:	3235-0080	
Expires:	March 31, 2018	
Estimated average burden		
hours per response:	1.7	

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number $\underline{001\text{-}7182}$

Is	suer: <u>MERRILL LYNC</u>	H & CO INC	
Ex	xchange: AMERICAN STOCK	EXCHANGE	
	LLC		
(Exact name of Issuer as specified in its charter,	and name of Exchange where security is lis	ted and/or registered)	
Address:	4 World Financial Ce	nter	
	New York NEW YO	RK 10080	
Telephon	e number:	(212) 449-1000	
(Address, including zip code, and telephone num	nber, including area code, of Issuer's principa	al executive offices)	
Strategic Return Notes	linked to the Biotech-Pharmaceur	tical Index, maturing November 1,	, 2007
(Description of class of securities)			
Please place an X in the box to designate registration:	the rule provision relied upon t	o strike the class of securities f	rom listing and
17 CFR 240.12d2-2(a)(1)			
▼ 17 CFR 240.12d2-2(a)(2)			
17 CFR 240.12d2-2(a)(3)			
17 CFR 240.12d2-2(a)(4)			
Pursuant to 17 CFR 240.120 securities from listing and/or with	():	· .	class of
Pursuant to 17 CFR 240.120 requirements of 17 CFR 240.120 and registration on the Exchang	d-2(c) governing the voluntary	ed with its rules of the Exchange withdrawal of the class of secu	
Pursuant to the requirements fo the Secur reasonable grounds to believe that it meet signed on its behalf by the undersigned du	ts all of the requirements for fili		
2007-11-05 By	Kerri L. Rar		, Corporate Actions Proxy Rulings
Date	Name	Title	
Form 25 and attached No applicable. See General II		nce with the provisions of 17 C	FR 240.19d-1 as

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES

The American Stock Exchange LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 15, 2007, pursuant to the provisions of Rule 12d2-2 (a). 17CFR240.12d2-2(a) (2)

The removal of Merrill Lynch & Co., Inc. Strategic Return Notes linked to the Biotech-Pharmaceutical Index, maturing November 1, 2007 is being effected because the Exchange knows or is reliably informed that the entire class of this security was redeemed or paid at maturity or retirement on November 1, 2007.

The security was suspended by the Exchange on November 2, 2007.